Emerging therapeutic paradigms in diabetes mellitus (DM) leverage the pleiotropic benefits of sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), extending beyond glycemic control to systemic immunomodulation. The gene discussed is SLC5A2; the disease is diabetes mellitus.